Background
Methods
Protocol and registration
Ιnformation sources and search strategy
Eligibility criteria
Participants
Interventions and comparators
Outcome measures
Study design
Study selection and data management
Risk of bias assessment
Data synthesis and analysis
Results
Review &Type of Study | Databases searched and last assessed | No. of primary studies (sample size) | Ethnicity | Age range (average age) in years | Treatment | Control | Overview outcomes |
---|---|---|---|---|---|---|---|
Walline et al. 2011 [5] SR & meta-analysis | CENTRAL, MEDLINE, EMBASE, LILACS, mRCT, ClinicalTrials.gov (10/2011) | 23 (4696) | Israel, Malaysia, China, USA, Finland, Hong Kong, Japan, Taiwan, Denmark | 6–18 | Undercorrection, multifocal spectacles, bifocal soft contact lenses, novel lenses, RGPCLs, anti-muscarinic medications | Full correction spectacles, SVLs, single vision contact lenses, placebo | Change in RE, change in AL |
Sherwin et al. 2012 [36] SR & meta-analysis | MEDLINE, EMBASE, Web of Science, CENTRAL (NA) | 23 (80–3009) | Singapore, Australia, Jordan, China, USA | 0.5–20 | Outdoor exposure | NA | Risk for myopia progression |
Wen et al. 2015 [33] SR & meta-analysis | MEDLINE, EMBASE, Cochrane Library, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (11/2014) | 8 (769) | Chinese, Caucasian, Japanese | 6–15 | OK | Single vision spectacles, contact lenses | Change in AL |
Xiong et al. 2017 [12] SR & meta-analysis | PubMed, EMBASE, Cochrane Library (12/2015) | 25 (50–5048) | China, Taiwan, Singapore, Australia, UK, USA, Turkey | 6–18a | Outdoor exposure | NA | Risk of myopia progression |
Gong et al. 2017 [9] SR & meta-analysis | PubMed, EMBASE, Cochrane Central Register of Controlled Trials (04/2016) | 19 (3137) | Taiwan, USA, Singapore, China, Hong Kong | 5–17 | Atropine | Atropine, control conditions | Myopia progression, adverse events |
Saw et al. 2002 [6] SR | MEDLINE, EMBASE, Cochrane Library, Science Citation Index (2000) | 26 (32–247) | Taiwan, USA, Finland, Denmark | NA | Atropine, timolol, bifocals, multifocal lenses, multifocal lenses + atropine, contact lenses | Tropicamide, cyclopentolate, lenses, bifocals, single vision spectacles | Change in RE |
Wei et al. 2011 [27] SR | CENTRAL, MEDLINE, EMBASE, AMED, LILACS, mRCT, ClinicalTrials.gov, NCCAM, CBM, CNKI, VIP (07/2011) | 2 (131) | Taiwan | < 18 | Auricular stimulation with 0.25% atropine, acupressure and interactive multimedia | Placebo, sham acupuncture, atropine eyedrops 0.25% or 0.5%, non-specific treatment, e.g. vitamin E, spectacles | Change in RE, change in AL |
Chassine et al. 2015 [38] SR | MEDLINE, Google Scholar (12/2014) | 19 (26–1209) | Αustralia, Singapore, China, USA, Malaysia, Canada, New Zealand, Russia | NA | Outdoor activity, atropine, undercorrection, bifocal (prismatic) spectacles, CLs, multifocal SCLs, OK, RGPCLs | Full correction, SVLs, atropine, PALs, SCLs | Myopia progression |
Shih et al. 2016 [28] SR | US FDA website, PubMed, ClinicalTrials.gov, Cochrane Library (04/2015) | 5 (96–400) | Taiwan, Singapore | 6–13 | Atropine 0.1–1% | Saline, cyclopentolate, atropine, tropicamide, atropine + multifocal spectacles, multifocal spectacles, SVLs | Change in RE, adverse events |
Song et al. 2011 [29] Meta-analysis | Cochrane Library, PubMed, US FDA website, ClinicalTrials.gov, European regulatory authorities, manufacturer’s product information sheets, CBMDISC (2009) | 6 (823) | Taiwan, Hong Kong, Singapore | 5–15 | Atropine 0.1–1% | Atropine, atropine + multifocal spectacles, multifocal spectacles/SVLs, auricular acupoints, tropicamide, cyclopentolate | Change in RE, change in AL |
Li et al. 2011 [30] Meta-analysis | MEDLINE, EMBASE, Cochrane Library, Science Citation Index, Chinese Clinical Trial Registry, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (10/2010) | 9 (1464) | USA, Hong Kong, China, Taiwan, Japan, Canada, Finland | 6–13 | Multifocal lenses (bifocal lenses, PALs) | SVLs | Change in RE, change in AL |
Li et al. 2014 [37] Meta-analysis | MEDLINE, EMBASE, Cochrane Library, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (04/2013) | 11 (1815) | Taiwan, Hong Kong, Singapore, United States | 8–15 | Atropine 0.025–1% | Placebo, Tropicamide, blank | Change in RE |
Sun et al. 2015 [31] Meta-analysis | MEDLINE, EMBASE (01/2014) | 7 (435) | Hong Kong, Japan, Spain, USA | 6–16 | OK | Spectacles, SCLs | Change in AL |
Si et al. 2015 [32] Meta-analysis | PubMed, EMBASE, Cochrane Library (11/2013) | 7 (435) | Hong Kong, Japan, Spain, USA | 6–16 | OK | SVLs, spectacles, SCLs | Change in AL |
Li et al. 2016 [10] Meta-analysis | MEDLINE, EMBASE, Cochrane Library, Chinese Clinical Trial Registry, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (01/2015) | 9 (667) | Hong Kong, Japan, China, Spain | 6–16 | OK | SVLs | Change in AL, adverse events |
Li et al. 2017 [11] Meta-analysis | MEDLINE, EMBASE, Cochrane Library, Chinese Clinical Trial Registry, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (05/2016) | 8 (587) | USA, China, Hong Kong, New Zealand, Japan, Spain | 6–18 | SCLs with concentric ring bifocal and peripheral add multifocal designs | single vision SCLs or spectacles | Change in RE, change in AL |
Cui et al. 2017 [35] Meta-analysis | MEDLINE, Cochrane, EMBASE, Google Scholar (09/2015) | 5 (673) | USA, Singapore, East Asia | 6–16 | RGPCLs | SCLs, spectacles, OK | Change in RE, change in AL |
Huang et al. 2016 [34] Network meta-analysis | MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, WHO international Clinical Trials Registry Platform, ClinicalTrials.gov (08/2014) | 30 (5387) | Israel, Malaysia, Hong Kong, USA, Denmark, Finland, Japan, China, New England, Singapore, Taiwan | < 18 | Atropine, pirenzepine, timolol, cyclopentolate, SVLs, OK, RGPCLs, bifocal spectacles outdoor activity, PALs, prismatic bifocals, peripheral defocus modifying spectacles and lenses, SCLs | Tropicamide, SVLs | Change in RE, change in AL |
Overlapping
Assessment of methodological quality
Outcome | Comparison | Number of subjects (primary studies) | Measure of effect (95% CI) | Direction of effect | I2 (%) |
---|---|---|---|---|---|
Change in refractive error | Undercorrected versus fully corrected spectacles | 142 (2) | MD = 0.15 (0.00 to 0.29) | Favours fully corrected spectacles | 0 |
Bifocal spectacles versus SVLs | 259 (2) | MD = − 0.09 (− 0.19 to 0.02) | Favours bifocal spectacles | 0 | |
1% atropine versus placebo - RCTs | 604 (3) | MD = − 0.78 (− 1.30 to − 0.25) | Favours atropine | 97 | |
1% atropine versus control - cohort studies | 798 (3) | MD = − 0.39 (− 0.59 to − 0.19) | Favours atropine | 26 | |
0.025 and 0.05% atropine versus control | 224 (3) | MD = − 0.51 (− 0.60 to − 0.41) | Favours atropine | 9 | |
0.01% atropine versus control | 60 (1) | MD = − 0.50 (− 0.76 to − 0.24) | Favours atropine | N/A | |
2% pirenzepine gel versus placebo | 84 (1) | MD = − 0.30 (− 0.51 to − 0.09) | Favours pirenzepine | N/A | |
RGPCLs versus spectacles or SCLs | 420 (2) | MD = − 0.08 (− 0.19 to 0.02) | Favours RGPCLs | 91 | |
Concentric ring bifocal SCLs versus SVSCLs | 264 (3) | MD = − 0.31 (− 0.60 to 0.02) | Favours concentric ring bifocal SCLs | 88 | |
Peripheral add multifocal SCLs versus SVLs - RCTs | 294 (5) | MD = − 0.23 (− 0.31 to − 0.14) | Favours peripheral add multifocal SCLs | 0 | |
ΟΚ versus SCLs or SVLs | 39 (1) | MD = − 0.27 (− 0.50 to − 0.04) | Favours OK | N/A | |
PALs versus SVLs | 206 (2) | MD = − 0.10 (− 0.21 to 0.00) | Favours PALs | 0 |
Outcome | Comparison | Number of subjects (primary studies) | Measure of effect (95% CI) | Direction of effect | I2 (%) |
---|---|---|---|---|---|
Change in axial length | Undercorrected versus fully corrected spectacles | 94 (1) | MD = 0.05 (− 0.01 to 0.11) | Favours full correction | N/A |
RGPCLs versus spectacles or SCLs | 415 (2) | MD = − 0.02 (− 0.05 to 0.10) | Favours spectacles/SCLs | 0 | |
2% pirenzepine gel versus placebo | 264 (2) | MD = − 0.10 (− 0.18 to − 0.01) | Favours pirenzepine | 0 | |
Concentric ring bifocal SCLs versus SVSCLs | 264 (3) | MD = − 0.12 (− 0.19 to − 0.06) | Favours concentric ring bifocal SCLs | 66 | |
1% atropine versus control | 586 (3) | MD = − 0.36 (− 0.41 to − 0.30) | Favours atropine | 46 | |
Peripheral add multifocal SCLs versus SVLs - RCTs | 294 (5) | MD = − 0.10 (− 0.14 to − 0.05) | Favours peripheral add multifocal SCLs | 37 | |
ΟΚ versus SCLs or SVLs | 524 (8) | MD = − 0.19 (− 0.21 to − 0.16) | Favours OK | 0 | |
PALs versus SVLs | 211 (2) | MD = − 0.08 (− 0.14 to 0.02) | Favours PALs | 65 |
Outcome | Comparison | Number of subjects (primary studies) | Measure of effect (95% CI) | Direction of effect | I2 (%) |
---|---|---|---|---|---|
Change in refractive error | Undercorrected versus fully corrected spectacles | 142 (2) | MD = 0.17 (0.12 to 0.23) | Favours fully corrected spectacles | 0 |
Bifocal spectacles versus single vision lens spectacles | 351 (3) | MD = − 0.19 (− 0.59 to 0.21) | Favours bifocal spectacles | 85 | |
1% atropine versus placebo | 400 (1) | MD = − 0.92 (− 1.08 to − 0.76) | Favours atropine | N/A | |
2% pirenzepine gel versus placebo | 74 (1) | MD = − 0.41 (− 0.70 to − 0.12) | Favours pirenzepine | N/A | |
RGPCLs versus spectacles or SCLs | 398 (2) | MD = − 0.16 (− 0.33 to − 0.00) | Favours RGPCLs | 92 | |
Concentric ring bifocal SCLs versus SVSCLs | 128 (1) | MD = − 0.20 (− 0.38 to − 0.02) | Favours concentric ring bifocal SCLs | N/A | |
Peripheral add multifocal SCLs versus SVLs | 99 (2) | MD = − 0.50 (− 0.65 to − 0.35) | Favours peripheral add multifocal SCLs | 0 | |
ΟΚ versus SCLs or SVLs | 39 (1) | MD = − 0.66 (−1.01 to − 0.31) | Favours OK | N/A | |
PALs versus SVLs | 940 (4) | MD = − 0.15 (− 0.40 to 0.11) | Favours PALs | 89 |
Outcome | Comparison | Number of subjects (primary studies) | Measure of effect (95% CI) | Direction of effect | I2 (%) |
---|---|---|---|---|---|
Change in axial length | Undercorrected versus fully corrected spectacles | 94 (1) | MD = 0.06 (− 0.04 to 0.16) | Favours full correction | N/A |
Bifocal spectacles versus single vision lens spectacles | 89 (1) | MD = − 0.20 (− 0.31 to − 0.09) | Favours bifocal spectacles | N/A | |
1% atropine versus placebo | 400 (1) | MD = − 0.36 (− 0.43 to − 0.29) | Favours atropine | N/A | |
2% pirenzepine gel versus placebo | 74 (1) | MD = − 0.12 (− 0.29 to 0.05) | Favours pirenzepine | N/A | |
RGPCLs versus spectacles or SCLs | 394 (2) | MD = 0.03 (− 0.05 to 0.12) | Favours spectacles or SCLs | 0 | |
Concentric ring bifocal SCLs versus SVSCLs | 128 (1) | MD = − 0.12 (− 0.20 to − 0.04) | Favours concentric ring bifocal SCLs | N/A | |
Peripheral add multifocal SCLs versus SVLs | 99 (2) | MD = − 0.13 (− 0.20 to − 0.06) | Favours peripheral add multifocal SCLs | 0 | |
ΟΚ versus SCLs or SVLs | 663 (11) | MD = − 0.27 (− 0.31 to − 0.23) | Favours OK | 0 | |
PALs versus SVLs | 791 (3) | MD = −0.10 (− 0.20 to 0.00) | Favours PALs | 78 |
Outcome | Comparison | Number of subjects (primary studies) | Measure of effect (95% CI) | Direction of effect | I2 (%) |
---|---|---|---|---|---|
Allergic or hypersensitivity reactions or discomfort | 1% atropine versus control | 446 (2) | OR = 8.91 (1.04, 76.03) | Favours control | 0 |
Blurred near vision | 1% atropine versus control | 540 (2) | OR = 9.47 (1.17, 76.78) | Favours control | 0 |
Contact lens-related discomfort/Unwillingness to wear contact lenses | Concentric ring bifocal SCLs versus SVSCLs | 261 (2) | OR = 0.95 (0.49, 1.81) | Favours concentric ring bifocal SCLs | 0 |
Mild corneal erosion | ΟΚ versus SCLs or SVLs | 151 (2) | 0R = 4.56 (0.49, 42.25) | Favours SCLs/SVLs | 0 |
Papillae/Follicles | 2% pirenzepine gel versus control | 323 (3) | OR = 3.21 (0.95, 10.88) | Favours control | 74 |
Medication residue on eyelids or eye | 2% pirenzepine gel versus control | 323 (3) | OR = 0.77 (0.38, 1.59) | Favours pirenzepine | 33 |
Abnormality of accommodation | 2% pirenzepine gel versus control | 323 (3) | OR = 16.92 (6.27, 45.64) | Favours control | 0 |
Itching, eye | 2% pirenzepine gel versus control | 323 (3) | OR = 1.01 (0.54, 1.90) | No difference | 0 |
Visual acuity decreased (subjectively) | 2% pirenzepine gel versus control | 323 (3) | OR = 3.89 (0.93, 16.27) | Favours control | 33 |
Injection | 2% pirenzepine gel versus control | 323 (3) | OR = 0.92 (0.22, 3.73) | Favours pirenzepine | 74 |
Fluorescein staining | 2% pirenzepine gel versus control | 323 (3) | OR = 0.57 (0.23, 1.44) | Favours pirenzepine | 45 |
Burn/Sting, eye, on instillation | 2% pirenzepine gel versus control | 323 (3) | OR = 1.84 (0.76, 4.46) | Favours control | 0 |
Eye/Vision, blurred | 2% pirenzepine gel versus control | 323 (3) | OR = 1.17 (0.52, 2.63) | Favours control | 0 |
Erythema, eyelids | 2% pirenzepine gel versus control | 110 (2) | OR = 0.69 (0.01, 41.23) | Favours pirenzepine | 76 |
Eyelid abnormality | 2% pirenzepine gel versus control | 110 (2) | OR = 1.73 (0.27, 11.12) | Favours control | 0 |
Photophobia | 2% pirenzepine gel versus control | 110 (2) | OR = 1.57 (0.35, 6.96) | Favours control | 0 |
Eye pain | 2% pirenzepine gel versus control | 110 (2) | OR = 2.07 (0.33, 12.98) | Favours control | 0 |
Cough, increased | 2% pirenzepine gel versus control | 323 (3) | OR = 1.06 (0.59, 1.92) | No difference | 0 |
Infection, respiratory | 2% pirenzepine gel versus control | 297 (2) | OR = 1.32 (0.69, 2.51) | Favours control | 0 |
Rhinitis/Sinusitis | 2% pirenzepine gel versus control | 323 (3) | OR = 1.08 (0.42, 2.76) | No difference | 28 |
Fever | 2% pirenzepine gel versus control | 297 (2) | OR = 1.07 (0.51, 2.24) | No difference | 0 |
Abdominal pain | 2% pirenzepine gel versus control | 323 (3) | OR = 2.42 (0.88, 6.62) | Favours control | 0 |
Headache | 2% pirenzepine gel versus control | 323 (3) | OR = 1.30 (0.66, 2.56) | Favours control | 0 |
Flu syndrome | 2% pirenzepine gel versus control | 297 (2) | OR = 0.54 (0.26, 1.13) | Favours pirenzepine | 0 |
Pharyngitis | 2% pirenzepine gel versus control | 323 (3) | OR = 1.07 (0.48, 2.37) | No difference | 0 |
Rash/Allergic reaction | 2% pirenzepine gel versus control | 323 (3) | OR = 1.77 (0.51, 6.12) | Favours control | 22 |
Cold, common | 2% pirenzepine gel versus control | 110 (2) | OR = 0.60 (0.25, 1.42) | Favours pirenzepine | 0 |
Accidental injury | 2% pirenzepine gel versus control | 110 (2) | OR = 2.32 (0.74, 7.22) | Favours control | 0 |